2026-09-22 19:15:05 UTC#351241duplicateconfirmednews
Amgen (AMGN) stock news
Amgen (AMGN) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-22 17:13:41 UTC#350701duplicateconfirmednews
Amgen's dazodalibep meets primary endpoint in Phase 3 Sjogren's disease trial
2026-09-22 13:22:45 UTC#349091duplicateconfirmednews
Amgen shares rise following positive Phase 3 trial results for Sjögren's disease therapy
2026-09-22 13:01:55 UTC#348947duplicateconfirmednews
Amgen autoimmune drug succeeds in late-stage trial, Reuters reports
2026-09-22 13:00:00 UTC#348908newconfirmednews
Amgen's dazodalibep meets primary endpoint in Phase 3 Sjogren's disease trial
2026-09-21 11:28:15 UTC#342048duplicateconfirmednews
Bristol-Myers Squibb weekly recap: Amgen Opdivo patent suit, $15.2B Hengrui deal, and $0.63 dividend
tradingviewimportance 0.30trust 0.70Bristol-Myers Squibb Company +0.30Amgen Inc. -0.40Jiangsu Hengrui Pharmaceuticals Co., Ltd. +0.50+2 entities
2026-09-17 23:57:24 UTC#330537newreportedanalysis
Novartis' pelacarsen failure poses negative read-through risk for Amgen's olpasiran, analysts say
yahooimportance 0.40trust 0.60Novartis AG -0.30Amgen Inc. -0.40Eli Lilly and Company -0.10+2 entities
2026-09-16 14:31:00 UTC#321453newconfirmednews
DelveInsight Report Projects Sjögren's Syndrome Market Growth Through 2036 Driven by New Targeted Therapies
2026-09-15 17:37:14 UTC#315922duplicateconfirmednews
Bristol Myers sues Amgen to block U.S. biosimilar of cancer drug Opdivo
2026-09-15 17:28:45 UTC#315859newconfirmednews
Bristol Myers and Ono sue Amgen to block U.S. biosimilar of cancer drug Opdivo
reutersimportance 0.60trust 0.90Bristol Myers Squibb Co. -0.20Amgen Inc. -0.30Ono Pharmaceutical Co., Ltd. -0.20+2 entities
2026-09-15 16:31:43 UTC#315499newconfirmednews
Amgen reports quarterly growth driven by IMDELLTRA and TEZSPIRE pipeline progress
2026-09-14 13:00:00 UTC#307482duplicateconfirmedpress release
Amgen receives FDA approval to reduce IMDELLTRA monitoring time for first two doses to 6-8 hours
pr_newswireimportance 0.30trust 1.00Amgen Inc. +0.50U.S. Food and Drug Administration +0.40IMDELLTRA +0.50+1 entities
2026-09-14 13:00:00 UTC#307458newconfirmednews
FDA approves Amgen IMDELLTRA label update, reducing first-dose monitoring to 6–8 hours
tradingviewimportance 0.50trust 0.80Amgen Inc. +0.40IMDELLTRA +0.40U.S. Food and Drug Administration +0.30
2026-09-14 12:45:00 UTC#307401newforecastanalysis
Yahoo recommends Amgen, Bausch Health, CareDx, and Centene as defensive plays ahead of expected Fed rate hike
yahooimportance 0.30trust 0.40Amgen Inc. +0.20Bausch Health Companies Inc. +0.20CareDx, Inc. +0.20+2 entities
2026-09-14 11:22:06 UTC#306795duplicateconfirmednews
Amgen shares pressured by Novartis pelacarsen trial failure despite $10B quarterly revenue
2026-09-13 14:29:16 UTC#303801duplicateconfirmedanalysis
Amgen shares remain pressured following Novartis pelacarsen Phase 3 trial failure
2026-09-12 10:48:13 UTC#302027newreportedopinion
Jim Cramer says Amgen downside limited after Novartis trial failure triggers sell-off
2026-09-11 20:30:10 UTC#300766newconfirmednews
Nasdaq gains on chip strength; Amgen shares drop following clinical trial setback
2026-09-10 16:44:34 UTC#293834newconfirmednews
Amgen reports quarterly revenue over $10B, highlights clinical progress for IMDELLTRA and TEZSPIRE
2026-09-08 20:40:39 UTC#283529updateconfirmednews